Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)

被引：0
|
作者：
Duran, C. Garcia [1 ]
Domenech, H. [2 ]
Javierre, G. Villacampa [3 ]
Farinas Madrid, L. [4 ]
Simonetti, S. [5 ]
Illescas, D. G. [1 ]
Serra Elizalde, V. [6 ]
Grau Bejar, J. F. [2 ]
Mazzeo, R. [7 ]
Llop-Guevara, A. [8 ]
Oaknin, A. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain
[2] VHIO Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Stat Dept, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Oncol Dept, Cellex Ctr, Barcelona, Spain
[5] Vall dHebron Inst Oncol VHIO, Mol Oncol Grp, Cellex Ctr, Barcelona, Spain
[6] Vall dHebron Inst Oncol VHIO, Expt Therapeut Grp Dept, Cellex Ctr, Barcelona, Spain
[7] Univ Udine, Med Oncol Dept, Dipartimento Area Med DAME, Udine, Italy
[8] Vall dHebron Inst Oncol VHIO, Expt Therapeut Grp, Cellex Ctr, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
779P
引用
收藏
页码：S526 / S527
页数：2
相关论文
共 43 条
  • [21] Homologous recombination deficiency (HRD) score predicts response to platinum-based chemotherapies in Chinese high grade serous ovarian cancer patients
    Wen, Hao
    Feng, Zheng
    Yuan, Wuzhou
    Zhou, Xiaoyan
    Wu, Xiaohua
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S108 - S109
  • [22] Feasibility and yield of offering genetic counseling to all patients with newly diagnosed high-grade epithelial ovarian cancer.
    Arnold, A. G.
    Bhatia, J.
    Phillips, M. F.
    Gardner, G. J.
    Bell-McGuinn, K. M.
    Aghajanian, C.
    Barakat, R. R.
    Offit, K.
    Kauff, N. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC)
    不详
    [J]. ESMO OPEN, 2023, 8 (01)
  • [24] Homologous Recombination Deficiency Testing for Advanced High-grade Tubo-ovarian/Primary Peritoneal Carcinoma: Experience from a Large Tertiary Centre
    Kret, A.
    Toss, M.
    Brammar, L.
    Sitaraaman, Bhuvanai H.
    [J]. JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S56 - S56
  • [25] Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
    Feng, Zheng
    Shao, Di
    Cai, Yuhang
    Bi, Rui
    Ju, Xingzhu
    Chen, Dongju
    Song, Chengcheng
    Chen, Xiaojun
    Li, Jin
    An, Na
    Li, Yunjin
    Zhou, Qing
    Xiu, Zhihui
    Zhu, Shida
    Wu, Xiaohua
    Wen, Hao
    [J]. JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [26] Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
    Zheng Feng
    Di Shao
    Yuhang Cai
    Rui Bi
    Xingzhu Ju
    Dongju Chen
    Chengcheng Song
    Xiaojun Chen
    Jin Li
    Na An
    Yunjin Li
    Qing Zhou
    Zhihui Xiu
    Shida Zhu
    Xiaohua Wu
    Hao Wen
    [J]. Journal of Ovarian Research, 16
  • [27] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
    Colombo, N.
    Gantzer, J.
    Ataseven, B.
    Cropet, C.
    Scambia, G.
    Herrero, A.
    Sevelda, P.
    Kobayashi, H.
    Vuylsteke, P.
    Mirza, M. R.
    Priou, F.
    Buderath, P.
    Pisano, C.
    Lainez, N.
    Guillemet, C.
    Burges, A.
    Sverdlin, R.
    El-Balat, A.
    Raban, N.
    Ray-Coquard, I. L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S614 - S614
  • [28] HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINATION IN PATIENTS WITH HIGH-GRADE SEROUS OVARIAN CANCER: REAL-WORD EXPERIENCE IN THE FRENCH CANCER INSTITUTE OF LORRAINE
    Harle, Alexandre
    Husson, Marie
    Hanriot, Idrissia
    Pax, Guillaume
    Gilson, Pauline
    Merlin, Jean-Louis
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A321 - A321
  • [29] Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
    Li, Yongmei
    Nie, Yufei
    Guo, Hongyan
    Guo, Hua
    Ha, Chunfang
    Li, Yuan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive
    Roy, S.
    Ghosh, J.
    Bhattacharjee, A.
    Ganguly, S.
    Biswas, B.
    Patel, Y. S.
    Pal, S.
    Karmakar, J.
    Mishra, D.
    Vinarkar, S.
    Dey, I.
    Demde, R.
    Bhaumik, J.
    Ghosh, A.
    Chakraborti, B.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1585 - S1585
12345